XML 88 R77.htm IDEA: XBRL DOCUMENT v3.25.3
Segment, Geographic and Other Revenue Information - Revenues by Products (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Sep. 29, 2024
Revenue from External Customer [Line Items]        
Revenues: $ 16,654 $ 17,702 $ 45,022 $ 45,864
Alliance revenues 2,298 1,900 6,684 6,140
Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 16,310 17,392 44,056 44,987
Biopharma [Member] | U.S. Commercial Division [Member]        
Revenue from External Customer [Line Items]        
Revenues: [1] 10,599 11,964 27,677 29,218
Biopharma [Member] | International Commercial Division [Member]        
Revenue from External Customer [Line Items]        
Revenues: 5,711 5,428 16,379 15,769
Pfizer CentreOne [Member]        
Revenue from External Customer [Line Items]        
Revenues: [2] 344 285 929 820
Pfizer Ignite [Member]        
Revenue from External Customer [Line Items]        
Revenues: 0 25 37 56
Total Alliance revenues [Member]        
Revenue from External Customer [Line Items]        
Alliance revenues 2,298 1,900 6,684 6,140
Royalty [Member]        
Revenue from External Customer [Line Items]        
Royalty revenue 436 384 1,170 992
Primary Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 7,646 9,060 18,882 21,224
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [3] 2,015 1,617 5,941 5,534
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 1,742 1,803 4,786 4,853
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [4] 1,225 2,703 2,144 4,989
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 1,151 1,422 2,097 1,970
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 412 337 1,019 870
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 279 356 553 557
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 100 81 272 246
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 721 742 2,071 2,204
Specialty Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 4,411 4,289 12,775 12,215
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 1,591 1,447 4,692 3,907
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 313 321 763 818
Specialty Care [Member] | Sulperazon (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 154 156 484 468
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 173 126 465 382
Specialty Care [Member] | Zavicefta (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 158 152 457 427
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 154 169 448 507
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 128 119 329 358
Specialty Care [Member] | Octagam [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 113 221 298 400
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 73 83 286 357
Specialty Care [Member] | Cresemba [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 83 67 267 213
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 79 63 206 152
Specialty Care [Member] | All other Hospital [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 985 1,041 2,971 3,082
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 407 323 1,112 1,145
Oncology [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 4,253 4,043 12,399 11,549
Oncology [Member] | Ibrance [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 1,057 1,087 3,083 3,272
Oncology [Member] | Xtandi [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [5] 578 561 1,602 1,474
Oncology [Member] | Padcev [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 464 409 1,432 1,144
Oncology [Member] | Oncology Biosimilars [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [6] 315 285 932 828
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 268 206 741 538
Oncology [Member] | Inlyta [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 226 247 688 736
Oncology [Member] | Adcetris [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [7] 215 268 687 804
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [8] 202 173 519 437
Oncology [Member] | Bosulif [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 150 161 450 474
Oncology [Member] | Tukysa [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 110 124 344 351
Oncology [Member] | Aromasin [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 114 87 333 257
Oncology [Member] | Orgovyx [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [9] 112 57 285 136
Oncology [Member] | Elrexfio [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 85 40 230 76
Oncology [Member] | Talzenna [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 47 36 133 91
Oncology [Member] | Tivdak [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 37 34 115 94
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: $ 272 $ 268 $ 824 $ 837
[1] Refer to Note 13A above.
[2] PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.
[3] Reflects alliance revenues and product revenues.
[4] The third quarter and first nine months of 2024 included $442 million of revenue recorded in connection with the creation of the U.S. Strategic National Stockpile of 1.0 million treatment courses, which we supplied at no cost to the U.S. government or taxpayers. The first nine months of 2024 also included a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023.
[5] Primarily reflects alliance revenues and royalty revenues.
[6] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Retacrit, Zirabev, Trazimera and Nivestym.
[7] Reflects product revenues and royalty revenues.
[8] Erbitux® is a registered trademark of ImClone LLC.
[9] Reflects alliance revenues.